CD4 dynamics, TS stage, and response
| Response . | No. . | CD4 change, median cells/mm3 (range) . | Patients with increase of 150 or more CD4 cells from baseline to response, no. (%) . | TS prognostic group . | |
|---|---|---|---|---|---|
| Good, no. (%) . | Poor, no. (%) . | ||||
| CR | 9 | 61 (−73 – +266) | 4 (50) | 4 (44) | 5 (56) |
| PR | 21 | −1 (−263 – +285) | 2 (9) | 9 (43) | 12 (57) |
| All resp | 30 | 5 (−263 – +285) | 6 (20) | 1 (50) | 1 (50) |
| PD | 4 | −72.5 (−164 – −14) | 0 | 0 (0) | 4 (100) |
| SD/PD | 6 | −27 (−164 – +221) | 1 (16.6) | 14 (39) | 22 (61) |
| Response . | No. . | CD4 change, median cells/mm3 (range) . | Patients with increase of 150 or more CD4 cells from baseline to response, no. (%) . | TS prognostic group . | |
|---|---|---|---|---|---|
| Good, no. (%) . | Poor, no. (%) . | ||||
| CR | 9 | 61 (−73 – +266) | 4 (50) | 4 (44) | 5 (56) |
| PR | 21 | −1 (−263 – +285) | 2 (9) | 9 (43) | 12 (57) |
| All resp | 30 | 5 (−263 – +285) | 6 (20) | 1 (50) | 1 (50) |
| PD | 4 | −72.5 (−164 – −14) | 0 | 0 (0) | 4 (100) |
| SD/PD | 6 | −27 (−164 – +221) | 1 (16.6) | 14 (39) | 22 (61) |
Patients with T1S1 according to Nasti et al18 were considered to have poor-prognosis KS. Of the 3 patients who had not received one month of highly active antiretroviral therapy at entry, one had a PR, one had a pathological CR, and one had a clinical CR. A Cochran-Armitage trend test shows no association between CD4 cell change and response (P2 = .19).